Live Breaking News & Updates on Mary hospital college
Stay updated with breaking news from Mary hospital college. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
January Therapeutics today announced the appointment of Dr. Paul Grint to the Board of Directors Share Article Dr. Paul Grint is bringing his experience as CMO, CEO (Private & Public Companies), Chairman of the Board, and Board Member to help January's Board SAN DIEGO (PRWEB) May 05, 2021 Dr. Grint has served as the Executive Chairman of the Board of Directors of Cardea Bio since April 2020. He also has served as a member of the Board of Directors and as a member of the compensation committee of Amplyx Pharmaceuticals, Inhibikase Therapeutics and Synedgen. From 2017 to 2019, Dr. Grint served as Chief Executive Officer of AmpliPhi Biosciences and as a member of AmpliPhi Bioscience’s Board of Directors from 2015 to 2019, additionally from 2014 to 2017 Dr. Grint served as Chief Executive Officer of Regulus Therapeutics, Inc., both publicly traded clinical stage biopharmaceutical companies.